Literature DB >> 19333401

Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments.

Carmen Vitiello1, Stefania Faraso, Nicolina Cristina Sorrentino, Giovanni Di Salvo, Edoardo Nusco, Gerardo Nigro, Luisa Cutillo, Raffaele Calabrò, Alberto Auricchio, Vincenzo Nigro.   

Abstract

BACKGROUND: The BIO14.6 hamster is an excellent animal model for inherited cardiomyopathy, because of its lethal and well-documented course, due to a spontaneous deletion of delta-sarcoglycan gene promoter and first exon. The muscle disease is progressive and average lifespan is 11 months, because heart slowly dilates towards heart failure. METHODOLOGY/PRINCIPAL
FINDINGS: Based on the ability of adeno-associated viral (AAV) vectors to transduce heart together with skeletal muscle following systemic administration, we delivered human delta-sarcoglycan cDNA into male BIO14.6 hamsters by testing different ages of injection, routes of administration and AAV serotypes. Body-wide restoration of delta-SG expression was associated with functional reconstitution of the sarcoglycan complex and with significant lowering of centralized nuclei and fibrosis in skeletal muscle. Motor ability and cardiac functions were completely rescued. However, BIO14.6 hamsters having less than 70% of fibers recovering sarcoglycan developed cardiomyopathy, even if the total rescued protein was normal. When we used serotype 2/8 in combination with serotype 2/1, lifespan was extended up to 22 months with sustained heart function improvement.
CONCLUSIONS/SIGNIFICANCE: Our data support multiple systemic administrations of AAV as a general therapeutic strategy for clinical trials in cardiomyopathies and muscle disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333401      PMCID: PMC2660610          DOI: 10.1371/journal.pone.0005051

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  39 in total

Review 1.  Cardiomyopathy in muscular dystrophies.

Authors:  Francesco Muntoni
Journal:  Curr Opin Neurol       Date:  2003-10       Impact factor: 5.710

2.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

3.  Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6.

Authors:  Michael J Blankinship; Paul Gregorevic; James M Allen; Scott Q Harper; Hollie Harper; Christine L Halbert; A Dusty Miller; Dusty A Miller; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

4.  The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  G Nigro; L I Comi; L Politano; R J Bain
Journal:  Int J Cardiol       Date:  1990-03       Impact factor: 4.164

Review 5.  Myopathy of hamster dystrophy: history and morphologic aspects.

Authors:  F Homburger
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

6.  Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy.

Authors:  F Muntoni; M Cau; A Ganau; R Congiu; G Arvedi; A Mateddu; M G Marrosu; C Cianchetti; G Realdi; A Cao
Journal:  N Engl J Med       Date:  1993-09-23       Impact factor: 91.245

7.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice.

Authors:  T Ragot; N Vincent; P Chafey; E Vigne; H Gilgenkrantz; D Couton; J Cartaud; P Briand; J C Kaplan; M Perricaudet
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

8.  Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy.

Authors:  K Matsumura; F M Tomé; H Collin; K Azibi; M Chaouch; J C Kaplan; M Fardeau; K P Campbell
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

9.  Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors.

Authors:  J Li; D Wang; S Qian; Z Chen; T Zhu; X Xiao
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

10.  Association of dystrophin and an integral membrane glycoprotein.

Authors:  K P Campbell; S D Kahl
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

View more
  16 in total

1.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

Review 3.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

Review 4.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

5.  An omega-3 fatty acid-enriched diet prevents skeletal muscle lesions in a hamster model of dystrophy.

Authors:  Roberta Fiaccavento; Felicia Carotenuto; Alba Vecchini; Luciano Binaglia; Giancarlo Forte; Enrico Capucci; Anna Maria Maccari; Marilena Minieri; Paolo Di Nardo
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

6.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

7.  Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.

Authors:  Ida Luisa Rotundo; Alessio Lancioni; Marco Savarese; Luca D'Orsi; Michele Iacomino; Gerardo Nigro; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  Hum Gene Ther       Date:  2013-04-04       Impact factor: 5.695

8.  Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study.

Authors:  Gerardo Nigro; Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Alberto Palladino; Luisa Politano
Journal:  Acta Myol       Date:  2012-10

9.  Improving the course of muscular dystrophy?

Authors:  Vincenzo Nigro
Journal:  Acta Myol       Date:  2012-10

10.  Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients.

Authors:  Luigia Passamano; Antonella Taglia; Alberto Palladino; Emanuela Viggiano; Paola D'Ambrosio; Marianna Scutifero; Maria Rosaria Cecio; Vito Torre; Francesco DE Luca; Esther Picillo; Orlando Paciello; Giulio Piluso; Gerardo Nigro; Luisa Politano
Journal:  Acta Myol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.